Literature DB >> 1838896

Evaluation of an interleukin-1 receptor antagonist in the rat acetic acid-induced colitis model.

T K Thomas1, P C Will, A Srivastava, C L Wilson, M Harbison, J Little, R S Chesonis, M Pignatello, D Schmolze, J Symington.   

Abstract

The anti-inflammatory activity of the IL-1 receptor antagonist, IL-1ra, was evaluated in the acetic acid (HOAc)-induced model of colitis in rats. Animals treated with 10 mg/kg IL-1ra or vehicle were evaluated for general health, acute phase response, and colonic in flammation 24 hours after the initiation of inflammation. A significant decrease in the accumulation of neutrophils in the colonic mucosa as measured by myeloperoxidase activity was seen in animals with HOAc induced colitis that were treated intraperitoneally with IL-1ra when compared to animals with colitis that had been treated with vehicle. IL-1ra also reduced colonic necrosis measured grossly, although there was no effect on the histology IL-1ra had a modest effect on the HOAc-induced acute phase response, as indicated by changes in the serum iron, albumin and transferrin, but the results were not statistically significant. The number of circulating erythrocytes and neutrophils was significantly increased in animals with HOAc-induced colitis and treated with IL-1ra, suggesting that IL-1ra under these experimental conditions inhibited the migration of neutrophils to the injured colon and also the overall intestinal necrosis in the colon as assessed by gross pathology. IL-1ra may be useful as an intestinal anti-inflammatory agent.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1838896     DOI: 10.1007/bf01993274

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  6 in total

1.  Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor.

Authors:  C H Hannum; C J Wilcox; W P Arend; F G Joslin; D J Dripps; P L Heimdal; L G Armes; A Sommer; S P Eisenberg; R C Thompson
Journal:  Nature       Date:  1990-01-25       Impact factor: 49.962

2.  Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein.

Authors:  D B Carter; M R Deibel; C J Dunn; C S Tomich; A L Laborde; J L Slightom; A E Berger; M J Bienkowski; F F Sun; R N McEwan
Journal:  Nature       Date:  1990-04-12       Impact factor: 49.962

3.  Inflammatory mediators of experimental colitis in rats.

Authors:  D Rachmilewitz; P L Simon; L W Schwartz; D E Griswold; J D Fondacaro; M A Wasserman
Journal:  Gastroenterology       Date:  1989-08       Impact factor: 22.682

4.  Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models.

Authors:  J E Krawisz; P Sharon; W F Stenson
Journal:  Gastroenterology       Date:  1984-12       Impact factor: 22.682

5.  Interleukin 1 in Crohn's disease.

Authors:  J Satsangi; R A Wolstencroft; J Cason; C C Ainley; D C Dumonde; R P Thompson
Journal:  Clin Exp Immunol       Date:  1987-03       Impact factor: 4.330

6.  Metabolism of arachidonic acid in acetic acid colitis in rats. Similarity to human inflammatory bowel disease.

Authors:  P Sharon; W F Stenson
Journal:  Gastroenterology       Date:  1985-01       Impact factor: 22.682

  6 in total
  18 in total

1.  IL-1beta and IL-6 excite neurons and suppress nicotinic and noradrenergic neurotransmission in guinea pig enteric nervous system.

Authors:  Y Xia; H Z Hu; S Liu; J Ren; D H Zafirov; J D Wood
Journal:  J Clin Invest       Date:  1999-05       Impact factor: 14.808

2.  The Importance of Intestinal Eotaxin-1 in Inflammatory Bowel Disease: New Insights and Possible Therapeutic Implications.

Authors:  Tomer Adar; Shimon Shteingart; Ami Ben-Ya'acov; Ariella Bar-Gill Shitrit; Dan M Livovsky; Shimrit Shmorak; Mahmud Mahamid; Bernardo Melamud; Fiona Vernea; Eran Goldin
Journal:  Dig Dis Sci       Date:  2016-02-13       Impact factor: 3.199

Review 3.  Targeting interleukins for the treatment of inflammatory bowel disease-what lies beyond anti-TNF therapy?

Authors:  Mairi H McLean; Markus F Neurath; Scott K Durum
Journal:  Inflamm Bowel Dis       Date:  2014-02       Impact factor: 5.325

4.  Quantitative PCR analysis of TNF-alpha and IL-1 beta mRNA levels in pediatric IBD mucosal biopsies.

Authors:  S Dionne; J Hiscott; I D'Agata; A Duhaime; E G Seidman
Journal:  Dig Dis Sci       Date:  1997-07       Impact factor: 3.199

5.  Human colon carcinomas constitutively express and shed type II IL-1 receptor, an IL-1 antagonist.

Authors:  Andrew W Stadnyk; Moorix M W Yeung; Sen Rong Yan
Journal:  Dig Dis Sci       Date:  2003-09       Impact factor: 3.199

6.  Lentiviral-vector-mediated expression of murine IL-1 receptor antagonist or IL-10 reduces the severity of endotoxin-induced uveitis.

Authors:  P Trittibach; S E Barker; C A Broderick; M Natkunarajah; Y Duran; S J Robbie; J W B Bainbridge; A J Smith; G-M Sarra; A D Dick; R R Ali
Journal:  Gene Ther       Date:  2008-06-26       Impact factor: 5.250

7.  Pharmacological activity of the second generation leukotriene B4 receptor antagonist, SC-53228: effects on acute colonic inflammation and hepatic function in rodents.

Authors:  D J Fretland; C P Anglin; D Widomski; D A Baron; T Maziasz; P F Smith
Journal:  Inflammation       Date:  1995-10       Impact factor: 4.092

8.  Small molecule-driven mitophagy-mediated NLRP3 inflammasome inhibition is responsible for the prevention of colitis-associated cancer.

Authors:  Wenjie Guo; Yang Sun; Wen Liu; Xingxin Wu; Lele Guo; Peifen Cai; Xuefeng Wu; Xudong Wu; Yan Shen; Yongqian Shu; Yanhong Gu; Qiang Xu
Journal:  Autophagy       Date:  2014-06       Impact factor: 16.016

9.  Phorbol myristate acetate ex vivo model of enhanced colonic epithelial permeability. Reactive oxygen metabolite and protease independence.

Authors:  M C Berin; M G Buell
Journal:  Dig Dis Sci       Date:  1995-10       Impact factor: 3.199

10.  Role of interleukin-1 in the pathogenesis of experimental shigellosis.

Authors:  P J Sansonetti; J Arondel; J M Cavaillon; M Huerre
Journal:  J Clin Invest       Date:  1995-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.